期刊文献+

血清总抗氧化能力和丙二醛水平在2型糖尿病颈动脉病变和视网膜病变中的变化 被引量:1

Changes of serum total antioxidant capacity and malondialdehyde concentration in type 2 diabetes with dabetic carotid disease and diabetic retinopathy
下载PDF
导出
摘要 目的:探讨糖尿病颈动脉病变和视网膜病变时的氧化应激表现。方法:选择92例2型糖尿病患者,检测血清总抗氧化能力(TAOC)、丙二醛(MDA)浓度及空腹血糖、糖化血清蛋白、糖化血红蛋白、肌酐、尿酸、纤维蛋白原、血脂水平,并进行对照分析。采用彩色多普勒超声判定糖尿病颈动脉病变,采用眼底荧光造影判定糖尿病视网膜病变,按结果将其分为3组:糖尿病无颈动脉病变和无视网膜病变组(DM1组)30例,糖尿病伴颈动脉病变组(DM2组)30例,糖尿病伴颈动脉病变和视网膜病变组(DM3组)32例。结果:(1)TAOC与MDA呈负相关(r=-0.312,P<0.01)。(2)DM2组、DM3组TAOC水平均明显低于DM1组(P<0.05)。(3)DM2组、DM3组MDA水平明显高于DM1组(P<0.05),DM3组MDA水平明显高于DM2组(P<0.05)。结论:氧化应激可能参与2型糖尿病大血管和微血管并发症的发病过程。 Objective: To investigate the role of oxidative stress in diabetic carotid disease and diabetic retinopathy. Methods: Serum level of the total antioxidant capacity (TAOC) and Malondialdehyde (MDA) were measured in 92 patients with type 2 diabetes. Meanwhile,fasting blood glucose, glycosylated serum protein, glycohemoglobin,serum creatinine,blood uric acid, fibrinogen and lipids were detected. The diabetic carotid disease was detected by colour Doppler and diabetic retinopathy was detected by fundus fluroescein angiography. The patients were divided into three groups, the diabetes group without diabetic carotid disease and diabetic retinopathy (DM1) (n = 30), the diabetes group with diabetic carotid disease (DM2) (n =30), the diabetes group with diabetic carotid disease and diabetic retinopathy (DM3) (n = 32). Results: (1) TAOC level was negative correlated with MDA level (r =-0. 312, P 〈0.01). (2) TAOC concentration was evidently lower in DM2 and DM3 than that in DMI(P〈0.05). (3)MDA concentration in DM2 and DM3 was significantly higher than that in DM1 (P 〈0. 05). MDA concentration in DM3 was significantly higher than that in DM2 (P 〈0. 05). Conclusion. Oxidative stress may participate in the development of type 2 diabetic micro-and macrovascular complications.
出处 《新疆医科大学学报》 CAS 2007年第3期230-233,共4页 Journal of Xinjiang Medical University
关键词 氧化应激 糖尿病视网膜病变 糖尿病颈动脉病变 oxidative stress diabetic retinopathy diabetic carotid disease
  • 相关文献

参考文献9

  • 1Rosen P,Naworth PP,King G,et al.The role of oxidative stress in the onset and progression of diabetes and its complications:a summary of a Congress Series sponsored by UNESCO-MCBN,the American Diabetes Association and the German Diabetes Society[J].Diabetes Metab Res Rev,2001,17:189-212.
  • 2Stadler K,Jenei V,Von Bolcshazy G,et al.Role of free radicals and reactive nitrogen species in the late complications of diabetes mellitus in rats[J].Orv Hetil,2004,145(21):1135-1140.
  • 3Blaszczak R,Kujawski K,Kedziora-Kornatowska K,et al.The total antioxidant capacity and low-molecular antioxidant concentration in plasma of type-2 diabetes patients with different stage of metabolic compensation and concomitant diabetic nephropathy[J].Pol Merkuriusz Lek,2005,18(103):29-32.
  • 4Nishikawa T,Sasahara T,Kiritoshi S,et al.Evaluation of urinary 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes[J].Diabetes Care,2003,26:1507-1512.
  • 5王丽宏,艾静,张巾超,李强,杨梅,杨宝峰.不同糖耐量者血清丙二醛及超氧化物歧化酶水平的变化[J].中国实用内科杂志,2005,25(4):311-312. 被引量:14
  • 6Sailaja DM,Suresh Y,Das AL,et al.Preservation of the antioxidant status in chemically-induced diabetes mellitus by melatonin[J].J Pineal Res,2000,29(2):108-115.
  • 7吴志贤,薛耀明,李晨钟,关美萍.2型糖尿病肾病患者血清晚期蛋白氧化产物的变化[J].第二军医大学学报,2005,26(9):1037-1039. 被引量:5
  • 8Gupta MM,Chari S.Lipid peroxidation and antioxidant status in patients with diabetic retinopathy[J].Indian J Physiol Pharmacol,2005,49(2):187-92.
  • 9Brownlee M.The pathobiology of diabetic complications:a unifying mechanism[J].Diabetes,2005,54:1615-1625.

二级参考文献13

  • 1Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus[J].Physiol Res,2002,51(6):597-604.
  • 2Puavilai G, Chanprasertyotin S, Sriphrapradaeng A. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria[J]. Diabetes Res Clin Pract,1999,44(1):21-26.
  • 3Telci A, Cakatay U, Salman S,et al. Oxidative protein damage in early stage type 1 diabetic patients[J]. Diabetes Res Clin Pract,2000,50(3):213-223.
  • 4Witko-Sarsat V, Nguyen-Khoa T, Jungers P,et al. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia[J]. Nephrol Dial Transplant,1999,14(Suppl 1):76-78.
  • 5Witko-Sarsat V, Friedlander M, Khoa TN,et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure[J].J Immunol,1998,161(5):2524-2532.
  • 6Naskalski JW, Marcinkiewicz J, Drozdz R. Myeloperoxidase-mediated protein oxidation: its possible biological functions[J]. Clin Chem Lab Med,2002 ,40(5):463-468.
  • 7Witko-Sarsat V, Descamps-Latscha B.Advanced oxidation protein products:novel uraemic toxins and pro-inflammatory mediators in chronic renal failure[J]?Nephrol Dial Transplant, 1997,12(7):1310.
  • 8Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins[J]?Kidney Int,2003,63(Suppl 84):S11-S14.
  • 9Je HD, Shin CY, Park HS,et al. The comparison of vitamin C and vitamin E on the protein oxidation of diabetic rats[J]. J Auton Pharmacol,2001,21(5-6):231-236.
  • 10Kaneda H, Taguchi J, Ogasawara K,et al. Increased level of advanced oxidation protein products in patients with coronary artery disease[J].Atherosclerosis,2002,162(1):221-225.

共引文献17

同被引文献15

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部